Zeit | Aktuelle Nachrichten |
---|
15:12 | Probiodrug appoints Ulrich Dauer as CEO |
12:42 | Redx appoints senior AstraZeneca executive as new CEO |
12:42 | PureTech Health appoints Joep Muijrers as chief financial officer |
12:12 | FDA advisors back Lilly/Incyte's rheumatoid arthritis drug |
12:12 | MHRA bans valproate without pregnancy prevention programme |
11:42 | EU reviewing MSD's Keytruda/chemo combo |
11:12 | FDA rejects Pfizer's Herceptin biosimilar |
11:12 | AstraZeneca lung cancer combo fails to hit targets |
Mo | Neil Levinson joins Accretio as strategy director |
Mo | Ministers write letter to Vertex over Orkambi debate |
Mo | Fresenius pulls out of $4.3bn Akorn merger |
Mo | Takeda ups its offer for Shire |
Mo | CHMP rejects AB Science's ALS drug |
Fr | Communications Team of the Year: Join our exclusive alumni of fellow Pharma winners! |
Fr | Clinical Researcher of the Year finalists to face toughest challenge yet |
Fr | Shire turns down Takeda's advances |
Fr | FDA advisors back approval of GW's Epidiolex |
Fr | US widens use of AstraZeneca' Tagrisso in lung cancer |
Fr | Merck sells consumer healthcare unit to P&G |
Fr | Marketer of the Year announces exciting new category |
Do | FDA clears first therapy for inherited rickets |
Do | Final NHS nod for Roche's RoActemra |
Do | GW's Epidiolex takes a leap toward US approval |
Do | MPs slate rate of progress on NHS cyber security |
Mi | CR UK, AACR form international cancer alliance |